Küsnacht, Zurich, Switzerland
Our team at Phytoceutics International AG thrives on the strategic internationalization of South African phytotherapeutics, a testament to my commitment to global healthcare trade and innovation. With an extensive background in New Business Development, Oncology, and Regulatory Affairs, we facilitate the sourcing of materials and products crucial for market dynamics. As a Portfolio Advisor at Aescap, my strategic insights contribute to the investment in groundbreaking public healthcare companies worldwide. Our success is driven by a deep understanding of the industry's pulse, enabling the identification of opportunities that hold potential for significant advances in medical science and patient care.
PhytoCeutics International AG is a Swiss based trading company that facilitates the internationalisation of South African produced phytotherapeutics besides assisting SA based companies in sourcing raw materials and finished products for the SA market.
Aescap is a Dutch privately held investment fund that invests in public healthcare companies around the world.
Cytecare is Bangalore's newest specialised cancer hospital, located a few miles from the International Airport. It features the most state-of-the-art diagnostic and therapeutic equipment available in the world operated by top clinicians to ensure optimal care for private patients.
Debx Medical Holding BV is the IP holder of the novel wound debridement treatment Debrichem or Debrix. This topical gel, registered as a medical device, causes the sterilisation of non-healing chronic wounds through a desiccant and energy producing chemical reaction leading to the destruction of the wound biofilm. This restarts the healing process in chronically infected wounds. The roll-out will happen in Europe, Africa and India in 2021.